Relapsed/Refractory Multiple Myeloma — Proceedings from a Session Held During the Society of Hematologic Oncology 2025 Annual Meeting

Non-Hodgkin Lymphoma and Chronic Lymphocytic Leukemia — Proceedings from the 2026 Annual ONS Congress

Featuring perspectives from Dr Farrukh T Awan, Dr Brad S Kahl, Ms Robin Klebig and Ms Mollie Moran, moderated by Dr Kahl, including the following topics: * Introduction: Biology of Non-Hodgkin Lymphoma (NHL) (00:00) * Current Role of CD20 x CD3 Bispecific Antibodies in NHL (4:49) * Role of Polatuzumab Vedotin in Diffuse Large B-Cell Lymphoma (DLBCL) (27:48) * Optimal Application of Loncastuximab Tesirine for Patients with DLBCL and Follicular Lymphoma (41:43) * Role of Bruton Tyrosine Kinase (BTK) Inhibitors Alone or with Anti-CD20 Antibodies for Patients with Newly Diagnosed Chronic Lymphocytic Leukemia (CLL) (1:00:43) * Combining BTK Inhibitors with Bcl-2 Inhibitors (1:31:15) * Current and Future Role of Noncovalent BTK Inhibitors in CLL (1:41:30) CME information and select publications [https://researchtopractice.com/ONS2026/NHLCLL/Video]

Strategies to Safely and Effectively Implement Antibody-Drug Conjugates — Proceedings from the 2026 Annual ONS Congress

Featuring perspectives from Ms Courtney Arn, Ms Jamie Carroll, Dr Edward B Garon, Dr Heather McArthur and Dr Kathleen N Moore, moderated by Dr Moore, including the following topics: * Introduction (0:00) * Overview of Antibody-Drug Conjugates (ADCs) (2:07) * Current and Future Role of HER2-Targeted ADCs for Breast Cancer (6:23) * Currently Available ADCs for Gynecologic Cancer Management (26:37) * Currently Available ADCs for Lung Cancer Management (44:07) * Current and Future Role of TROP2-Targeted ADCs for Metastatic Breast Cancer (56:55) * Other ADCs That May Soon Reach the Clinic for Advanced Gynecologic Cancers (1:15:07) * Promising Investigational Strategies Employing ADCs for Lung Cancer (1:25:01) NCPD information and select publications [https://researchtopractice.com/activity/new-paradigms-novel-agents-and-what-it-means-for-the-oncology-nurse-strategies-to-safely-and-effectively-implement-antibody-drug-conjugates/?chapter=0]

Non-Muscle-Invasive and Muscle-Invasive Bladder Cancer — Proceedings from the 2026 Annual ONS Congress

Featuring perspectives from Dr Alexandra Drakaki, Ms Krisztina Emodi, Dr Terence Friedlander and Ms Margarita Huober, moderated by Dr Friedlander, including the following topics: * Introduction: Basic Biology of Nonmetastatic Urothelial Bladder Cancer (UBC) (0:00) * Systemic Therapy for Cisplatin-Eligible Patients with Muscle-Invasive Bladder Cancer (MIBC) (13:35) * Evolving Approach to Systemic Therapy for Cisplatin-Ineligible Patients with MIBC (37:13) * Immune Checkpoint Inhibitors in Non-Muscle-Invasive Bladder Cancer (58:55) * Novel Intravesical Therapies for Nonmetastatic UBC (1:10:20) NCPD information and select publications [https://researchtopractice.com/ONS2026/nmBladder/Video]

Endometrial Cancer — Proceedings from the 2026 Annual ONS Congress

Featuring perspectives from Dr Dana M Chase, Ms Sarah Karpen, Dr J Alejandro Rauh-Hain and Ms Jaclyn Shaver, moderated by Dr Chase, including the following topics: * Introduction: Biology of Endometrial Cancer (EC) (0:00) * First-Line Therapy for Advanced or Recurrent EC (14:15) * Potential Benefits of PARP Inhibition Combined with Immunotherapy in Advanced EC (35:13) * Role of Lenvatinib/Pembrolizumab in the Management of Progressive Advanced EC (57:48) * Other Nursing Considerations in the Care of Patients with Advanced EC (1:17:28) NCPD information and select publications [https://researchtopractice.com/ONS2026/Endometrial/Video]

Nonmelanoma Skin Cancers — An Interview with Dr Nikhil Khushalani

Dr Nikhil I Khushalani from the Moffitt Cancer Center in Tampa, Florida, discusses available and novel treatment strategies for nonmelanoma skin cancers. NCPD information and select publications here [https://www.researchtopractice.com/ONU2026/NonmelanomaSkin/Video].